04:50 AM EDT, 06/23/2025 (MT Newswires) -- Alvotech ( ALVO ) and Advanz Pharma said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending approval for AVT06, Alvotech's ( ALVO ) proposed biosimilar to Eylea.

the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending approval for AVT06, Alvotech's ( ALVO ) proposed biosimilar to Eylea.

The drug approval is indicated for the treatment of adults with neovascular age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion, visual impairment due to diabetic macular oedema, and visual impairment due to myopic choroidal neovascularization, the companies said.

Alvotech ( ALVO ) develops and commercializes AVT06 while Advanz Pharma oversees s responsible for registration and retains commercialization rights for most countries in Europe, the companies said.